Genasense Updates Phase III Results in Malignant Melanoma
Genta has released long-term follow-up results from the company's Phase III trial of Genasense (oblimersen sodium) injection in patients with advanced malignant melanoma.
Earlier analyses showed that the addition of Genasense to chemotherapy yielded a statistically significant increase in overall response, complete response and time to progression.
Extended follow-up for a minimum of 24 months in all patients has revealed that patients treated with Genasense also achieved a significant increase in durable response (responses longer than six months duration) and a near-significant trend toward increased overall survival.
Lastly, the analyses showed that a blood test could be used to identify patients who were likely to derive maximal benefit from Genasense treatment.